MUMBAI (Reuters) - Dr Reddy's Laboratories Ltd, India's second-largest drugmaker by sales, said it will buy some established brands of Belgian drugmaker UCB SA in India, Nepal, Sri Lanka and Maldives for 8 billion rupees ($128.38 million).
The deal will help Dr Reddy's strengthen its presence in dermatology, pediatrics and respiratory products, the company said in a statement to the Bombay Stock Exchange.
The acquired business generated full-year 2014 revenue of about 1.5 billion rupees, Dr Reddy's said.
Reuters reported last month that Dr Reddy's was in talks with UCB for a deal concerning the latter's Indian operations, citing a source with direct knowledge of the matter.
($1 = 62.3150 rupees)
Also Read
(Reporting by Zeba Siddiqui in Mumbai; Editing by Sunil Nair)